Mr. Ryoichi Tanaka Joins Telix Japan as Chief Operating Officer

06 August 2021 | News

The radiology and nuclear medicine expert will boost the pivotal studies of investigational imaging productsTLX250-CDx for renal cancer, and Illuccix® for prostate cancer

Telix Pharmaceuticals Limited announced that Mr. Ryoichi Tanaka has joined the Telix Japan leadership team in the role of Chief Operating Officer and Head of Business Development.

Mr. Tanaka joins from Siemens Healthcare K.K. where most recently he was Head of Medical Policy & Public Affairs. Ryoichi brings nearing to four decades of expertise in radiology and molecular imaging across sales and marketing, business development, and medical policy and government affairs. He currently holds two public positions as Vice Chair of the Committee of Research and Development of JIRA (Japan Medical Imaging and Radiological Systems Industries Association) and Director of Reimbursement of the European Business Council (EBC) in Japan, a position he has held since 2016.

On joining Telix, Mr. Tanaka stated, "I am very pleased to join Telix, a global leader and innovator in molecularly targeted radiation (MTR). I look forward to making our MTR products available to Japanese patients and pioneering the Japanese market. Patient access to nuclear medicines in Japan has been limited to date and Telix has an opportunity to change the paradigm. I am proud to be part of that journey."

Telix Japan President, Dr. Shintaro Nishimura added, "I am delighted to welcome Ryoichi to Telix Japan at this important time in our Company's evolution. His pedigree in radiology and nuclear medicine, combined with broad experience in business and medical policy, will be instrumental as we prepare for Japanese pivotal studies of our lead investigational imaging products TLX250-CDx for renal cancer, and Illuccix® for prostate cancer."

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States